Mezzasalma Advisors LLC Buys 204 Shares of Novartis AG (NYSE:NVS)

Mezzasalma Advisors LLC boosted its stake in Novartis AG (NYSE:NVS) by 4.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,244 shares of the company’s stock after acquiring an additional 204 shares during the period. Mezzasalma Advisors LLC’s holdings in Novartis were worth $603,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NVS. Founders Financial Securities LLC boosted its position in shares of Novartis by 3.4% during the 2nd quarter. Founders Financial Securities LLC now owns 2,832 shares of the company’s stock valued at $301,000 after purchasing an additional 94 shares in the last quarter. Steigerwald Gordon & Koch Inc. boosted its holdings in shares of Novartis by 4.8% during the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after buying an additional 95 shares in the last quarter. NBC Securities Inc. grew its position in shares of Novartis by 0.9% during the 2nd quarter. NBC Securities Inc. now owns 10,492 shares of the company’s stock worth $1,116,000 after buying an additional 97 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Novartis by 5.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,013 shares of the company’s stock valued at $196,000 after acquiring an additional 98 shares in the last quarter. Finally, Portside Wealth Group LLC lifted its position in shares of Novartis by 3.4% during the 2nd quarter. Portside Wealth Group LLC now owns 3,000 shares of the company’s stock valued at $319,000 after acquiring an additional 99 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Trading Down 0.1 %

Shares of Novartis stock opened at $116.44 on Thursday. The firm has a market cap of $238.00 billion, a PE ratio of 15.73, a P/E/G ratio of 1.71 and a beta of 0.57. Novartis AG has a 1 year low of $92.19 and a 1 year high of $120.92. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. The stock has a fifty day moving average price of $116.09 and a 200-day moving average price of $107.69.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.10. The business had revenue of $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a net margin of 33.76% and a return on equity of 34.56%. During the same quarter last year, the company posted $1.83 earnings per share. Equities research analysts anticipate that Novartis AG will post 7.52 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on NVS shares. Bank of America lowered shares of Novartis from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Novartis in a report on Friday, July 19th. Barclays upgraded Novartis to a “strong sell” rating in a report on Monday, June 24th. The Goldman Sachs Group restated a “neutral” rating and set a $121.00 price target (up previously from $119.00) on shares of Novartis in a research note on Thursday, September 5th. Finally, Jefferies Financial Group lowered shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novartis currently has an average rating of “Hold” and a consensus price target of $120.70.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.